# A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

> **NCT04258956** · PHASE2 · COMPLETED · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 58 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04258956
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-30
- **Primary completion:** 2021-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258956, "A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04258956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*